CVSNYSERetail-Drug Stores and Proprietary StoresFiscal year ends December 31
CVS HEALTH Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$92.68+0.32 (+0.35%)
Close on Oct 19, 2026
- Market cap
- $119.28B
- P/E (TTM)
- 24.6
- Dividend yield
- 2.87%
CVS HEALTH Corp revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Health Services | $200.54B | $195.20B | $190.43B | $186.20B | $181.06B | $176.78B | $173.61B | $175.73B | $178.49B | $182.54B | $186.84B | $181.47B | 48.3% | +10.8% |
| Health Care Benefits | $145.80B | $144.52B | $143.35B | $140.02B | $137.02B | $133.24B | $130.67B | $124.43B | $117.73B | $112.01B | $105.65B | $101.94B | 35.1% | +6.4% |
| Pharmacy & Consumer Wellness | $139.68B | $139.44B | $139.37B | $135.22B | $131.43B | $127.69B | $124.50B | $122.17B | $118.62B | $117.57B | $116.76B | $114.29B | 33.7% | +6.3% |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Products | $260.08B | $254.47B | $249.91B | $244.78B | $239.86B | $235.47B | $231.52B | $234.76B | $236.39B | $240.72B | $245.14B | $239.64B | 62.7% | +8.4% |
| Services | $15.92B | $15.43B | $15.18B | $15.27B | $15.62B | $15.95B | $16.24B | $15.42B | $14.68B | $13.72B | $12.29B | $11.41B | 3.8% | +2.0% |
By region
From the segment and revenue-disaggregation notes of Cvs Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.